OM
Opaleye Management Portfolio holdings
AUM
$494M
This Quarter Return
+4.61%
1 Year Return
+68.17%
3 Year Return
+608.37%
5 Year Return
+807.76%
10 Year Return
+24,567.28%
AUM
$418M
AUM Growth
+$418M
(+25%)
Cap. Flow
+$102M
Cap. Flow
% of AUM
24.46%
Top 10 Holdings %
Top 10 Hldgs %
66.46%
Holding
52
New
11
Increased
13
Reduced
15
Closed
5
Top Buys
| 1 |
SLRN
ACELYRIN
SLRN
|
$86.9M |
| 2 |
Geron
GERN
|
$7.54M |
| 3 |
CBAY
Cymabay Therapeutics
CBAY
|
$6.21M |
| 4 |
Acadia Pharmaceuticals
ACAD
|
$5.2M |
| 5 |
Intellia Therapeutics
NTLA
|
$4.89M |
Top Sells
| 1 |
Arcutis Biotherapeutics
ARQT
|
$5.52M |
| 2 |
TELA Bio
TELA
|
$4.99M |
| 3 |
Phathom Pharmaceuticals
PHAT
|
$3.54M |
| 4 |
JNCE
Jounce Therapeutics, Inc. Common Stock
JNCE
|
$3.03M |
| 5 |
Cytokinetics
CYTK
|
$2.53M |
Sector Composition
| 1 | Healthcare | 98.38% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
26
Cytokinetics
CYTK
$5.98B
| $4.24M | 1.01% |
130,000
-77,500
| -37% | -$2.53M |
|
27
Trevi Therapeutics
TRVI
$871M
| $4.07M | 0.97% |
1,701,500
+865,700
| +104% | +$2.07M |
|
28
Gossamer Bio
GOSS
$587M
| $4.04M | 0.97% |
+3,370,000
| New | +$4.04M |
|
29
4D Molecular Therapeutics
FDMT
$302M
| $4.01M | 0.96% |
221,700
-92,300
| -29% | -$1.67M |
|
|
NYXH
30
Nyxoah
NYXH
$220M
| $3.56M | 0.85% |
445,000
+387,415
| +673% | +$3.1M |
|
|
EDAP
31
EDAP TMS
EDAP
$103M
| $3.5M | 0.84% |
380,000
-2,400
| -0.6% | -$22.1K |
|
32
Karyopharm Therapeutics
KPTI
$61.4M
| $3.2M | 0.76% |
1,785,000
-1,025,800
| -36% | -$1.84M |
|
33
Iovance Biotherapeutics
IOVA
$800M
| $2.96M | 0.71% |
421,000
| – | – |
|
34
Stereotaxis
STXS
$246M
| $2.95M | 0.71% |
3,074,995
+2,207,895
| +255% | +$2.12M |
|
35
Astria Therapeutics
ATXS
$394M
| $2.54M | 0.61% |
305,000
+3,000
| +1% | +$25K |
|
36
Codexis
CDXS
$218M
| $1.89M | 0.45% |
675,000
-75,000
| -10% | -$210K |
|
37
Fortress Biotech
FBIO
$87.8M
| $1.82M | 0.44% |
3,310,000
-1,263,600
| -28% | -$695K |
|
38
Sutro Biopharma
STRO
$85.6M
| $1.43M | 0.34% |
+307,000
| New | +$1.43M |
|
39
Black Diamond Therapeutics
BDTX
$164M
| $1.39M | 0.33% |
+275,000
| New | +$1.39M |
|
|
TCON
40
DELISTED
TRACON Pharmaceuticals, Inc. Common Stock
TCON
| $1.39M | 0.33% |
4,764,508
| – | – |
|
41
ProQR Therapeutics
PRQR
$256M
| $1.06M | 0.25% |
653,000
| – | – |
|
|
JNCE
42
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
| $918K | 0.22% |
669,944
-2,210,056
| -77% | -$3.03M |
|
43
Verastem
VSTM
$585M
| $759K | 0.18% |
+102,000
| New | +$759K |
|
44
Xoma
XOMA
$421M
| $595K | 0.14% |
275,000
+32,000
| +13% | +$69.2K |
|
|
IGMS
45
DELISTED
IGM Biosciences
IGMS
| $586K | 0.14% |
+63,500
| New | +$586K |
|
46
Fulcrum Therapeutics
FULC
$353M
| $474K | 0.11% |
+143,600
| New | +$474K |
|
47
Kezar Life Sciences
KZR
$28.5M
| $242K | 0.06% |
98,796
-526,204
| -84% | -$1.29M |
|
48
Relay Therapeutics
RLAY
$709M
| – | – |
-125,500
| Closed | -$2.07M |
|
|
49
Phathom Pharmaceuticals
PHAT
$843M
| – | – |
-496,000
| Closed | -$3.54M |
|
50
Modular Medical
MODD
$39.7M
| – | – |
-183,500
| Closed | -$266K |
|